Lipocine

Lipocine is a specialty pharmaceutical company focused on developing innovative oral treatment alternatives for use in men’s and women’s health using its proprietary drug delivery technologies. Lipocine product development pipeline entails repositioning of established drugs with significantly improved patient compliance through an efficient 505(b) (2) regulatory pathway strategy. LPCN 1021 is an oral testosterone replacement product candidate with positive topline Phase 3 efficacy results and is currently in an ongoing safety extension phase. The product is targeted to treat symptoms of low testosterone for hypogonadal men in need of testosterone replacement therapy. We believe LPCN 1021 is a safer alternative to current non-orals; reliably restores and maintains testosterone levels; is more convenient than currently marketed products and has the potential to improve patient’s therapy, adherence and retention. LPCN 1111 is a novel next generation oral testosterone product candidate currently in Phase 2 with successful demonstration for once daily oral dosing for testosterone replacement therapy. LPCN 1107 is targeted to be the first oral hydroxyprogesterone caproate product candidate indicated for the prevention of recurrent preterm birth and is currently in Phase 1.
Company Growth (employees)
Type
Public
HQ
Salt Lake City, US
Founded
1997
Size (employees)
14 (est)
Lipocine was founded in 1997 and is headquartered in Salt Lake City, US

Lipocine Office Locations

Lipocine has an office in Salt Lake City
Salt Lake City, US (HQ)
202 675 Arapeen Dr

Lipocine Data and Metrics

Lipocine Financial Metrics

USD

Net income (Q1, 2017)

(4.9 m)

EBIT (Q1, 2017)

(4.9 m)

Market capitalization (15-Aug-2017)

80.4 m

Cash (31-Mar-2017)

6.9 m
Lipocine's current market capitalization is $80.4 m.
USDY, 2013FY, 2016

R&D expense

8.1 m

General and administrative expense

10.4 m

Operating expense total

10.7 m19.2 m

EBIT

(10.7 m)(19.2 m)

Income tax expense

55 k(752)

Net Income

(10.6 m)(19 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

R&D expense

6 m3.2 m1.9 m3.2 m4.7 m2.7 m2.6 m1.5 m3.1 m

General and administrative expense

1 m871.8 k1.1 m1.1 m1.7 m4.4 m3.2 m1.4 m1.8 m

Operating expense total

7 m4.1 m3 m4.3 m6.4 m7.1 m5.8 m2.9 m4.9 m

EBIT

(7 m)(4.1 m)(3 m)(4.3 m)(6.4 m)(7.1 m)(5.8 m)(3.3 m)(4.9 m)

Income tax expense

(200)(700)(700)

Net Income

(7 m)(4.1 m)(3 m)(4.2 m)(6.4 m)(7 m)(5.8 m)(3.2 m)(4.9 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

45.3 m27.7 m20 m5.6 m

Current Assets

46 m27.9 m44.9 m27.2 m

PP&E

28.8 k

Total Assets

46.1 m28 m45.4 m27.3 m

Accounts Payable

1 m306.3 k507.1 k245.9 k

Current Liabilities

1.3 m1.6 m3.4 m1.3 m

Total Liabilities

1.3 m

Additional Paid-in Capital

92.7 m94.6 m128.5 m131.5 m

Retained Earnings

(47.9 m)(68.2 m)(86.4 m)(105.4 m)

Total Equity

26.4 m42 m26 m

Financial Leverage

1.1 x1.1 x1.1 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

34.2 m31.7 m24.8 m38.3 m23.9 m14.1 m12.4 m4.7 m6.9 m

Current Assets

35.4 m32 m25 m44.1 m42.3 m38.6 m33.2 m29.4 m27.1 m

Total Assets

35.5 m32 m25.1 m53.8 m48.4 m38.8 m33.3 m29.6 m27.2 m

Accounts Payable

641.8 k399.1 k379.5 k398.8 k456.8 k1.1 m989 k865 k853.5 k

Current Liabilities

1.7 m2.1 m1.3 m1.7 m2.2 m3 m2.6 m1.6 m2.3 m

Additional Paid-in Capital

94 m94.2 m95 m127.6 m128.1 m129.3 m130 m130.5 m135.2 m

Retained Earnings

(60.1 m)(64.2 m)(71.2 m)(75.4 m)(81.8 m)(93.5 m)(99.2 m)(102.5 m)(110.3 m)

Total Equity

33.8 m30 m23.7 m52.1 m46.2 m35.8 m30.8 m28 m24.9 m

Financial Leverage

1 x1.1 x1.1 x1 x1 x1.1 x1.1 x1.1 x1.1 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(10.6 m)(20.4 m)(18.2 m)(19 m)

Depreciation and Amortization

21.8 k14.6 k26.7 k32 k

Accounts Payable

668.8 k(449.6 k)200.8 k(261.2 k)

Purchases of PP&E

(1.2 k)(59.6 k)(28.7 k)(59.7 k)

Cash From Financing Activities

48.5 m(255.1 k)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(7 m)(4.1 m)(3 m)(4.2 m)(6.4 m)(7 m)(5.8 m)(3.2 m)(4.9 m)

Accounts Payable

641.8 k399.1 k379.5 k398.8 k456.8 k1.1 m989 k865 k853.5 k
Y, 2017

Financial Leverage

1.1 x

Lipocine Market Value History

Traffic Overview of Lipocine

Lipocine News and Updates

BRIEF-Lipocine gets complete response letter for LPCN 1021 from FDA

* Lipocine receives complete response letter (crl) for LPCN 1021 From U.S. Food And Drug Administration

Lipocine Company Life and Culture

You may also be interested in